Leading alternative legal services provider makes third acquisition in nine months | 1yr
Leading alternative legal services provider makes third acquisition in nine months | 1yr
US firm beefs up environmental, safety and health practice with group led by partners Peter Sellar and Gerard McElwee | 1yr
Highly-regarded trial lawyer Allison Brown joins with four more partners | 1yr
Closure follows office head Shaobin Zhu defecting to DLA Piper last year | 1yr
This second edition delivers a comparative analysis of cryptoasset regulation in a rapidly evolving global legal landscape. | 2mos
Editors:
Sarah Smith joins as head of Simmons’ UK competition and antitrust team following predecessor’s exit for Kirkland last year | 1yr
US firm's fourth European office to offer privacy and data security services to tech and life sciences clients | 1yr
Joiners arrive from Hausfeld, Pinsent Masons and Gowling WLG | 1yr
Patent litigator Alexander Ritter marks latest in string of European hires by the US firm | 1yr
Jones Day, Linklaters and Arnold & Porter also called in for the largest healthcare buyout of 2024 | 1yr
Results show EU Commission’s security initiative is having success in tackling counterfeits | 1yr
Firm says hire underscores commitment to strengthening UK IP practice | 1yr
Merged firm to house 230 professionals and operate under Venner Shipley name | 1yr
Laurence Lieberman led his former firm’s life sciences commercial disputes group | 1yr
Firm chair Alden Millard points to bolstering global M&A bench as a ‘priority’ | 1yr
Thomas Kendra brings emerging markets expertise to his new firm notably through his Africa work | 1yr
Jenny Davies joins as a partner in Cooley’s London life sciences partnering and licensing practice | 1yr
Californian court finds ‘strong likelihood’ that ex-employee took trade secret information to benefit his own company | 1yr
Latest lawsuits in mounting patent litigation over vaccines against the two viruses | 1yr
Arrival of Tim Powell continues US firm’s European IP push | 1yr
GSK’s two patents declared invalid as both attempt to launch first RSV vaccine in UK market | 1yr